Global Graft Versus Host Disease (GvHD) Treatment Market 2023

September 2023 | 93 pages | ID: G30CEAF60F6FEN
Gen Consulting Company

Abstracts

The GvHD treatment market was valued at USD 678.1 million in 2022 and is projected to reach USD 1,039 million by 2029, with a CAGR of 6.0%. GvHD occurs when the donor's T-cells attack the recipient's healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Market Segmentation
The market is segmented based on various factors, including drug class, treatment type, gender, and geography.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males

Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC - China, Japan

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

Competitive Landscape
Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.

Scope of the Report
To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.
To identify drivers and challenges for the global GvHD treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

Why Choose This Report
Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience

PART 2. RESEARCH METHODOLOGY

2.1 Primary Research
2.2 Secondary Research

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Drivers
4.3 Restraints

PART 5. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY DRUG CLASS

5.1 Calcineurin inhibitors
5.2 Corticosteroids
5.3 Kinase inhibitors
5.4 TNF-alpha inhibitors
5.5 Others

PART 6. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY TREATMENT TYPE

6.1 Acute GVHD
6.2 Chronic GVHD
6.3 GVHD prophylaxis

PART 7. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GENDER

7.1 Females
7.2 Males

PART 8. GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET BY GEOGRAPHY

8.1 North America
8.2 Europe
8.3 APAC

PART 9. COMPANY PROFILES

9.1 AltruBio, Inc.
9.2 ASC Therapeutics Inc.
9.3 Bristol-Myers Squibb Company
9.4 Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd.
9.5 Elsalys Biotech SAS
9.6 Equillium, Inc.
9.7 F. Hoffmann-La Roche AG
9.8 Genentech, Inc.
9.9 GSK plc
9.10 Incyte Corporation
9.11 Janssen Global Services, LLC
9.12 Jazz Pharmaceuticals plc
9.13 JCR Pharmaceuticals Co., Ltd.
9.14 Kadmon Corporation (Sanofi S.A.)
9.15 MaaT Pharma SA
9.16 Mallinckrodt PLC
9.17 medac GmbH
9.18 Merck Corporation
9.19 Mesoblast Limited
9.20 MiNK Therapeutics, Inc.
9.21 Neovii Pharmaceuticals AG
9.22 Novartis AG
9.23 Pharmacyclics LLC
9.24 Pluri Inc.
9.25 REGiMMUNE Corporation
9.26 Sun Pharmaceutical Industries Ltd.
9.27 Syndax Pharmaceuticals, Inc.
9.28 Takeda Pharmaceutical Company Limited
9.29 Xenikos B.V.
DISCLAIMER